Treatment of vitiligo with a chimeric monoclonal antibody to CD20: A pilot study

Clinical and Experimental Immunology

Volumn 174, Issue 2, 2013, Pages 229-236

  Ruiz Arguelles A ^a,d   Garcia Carrasco M ^b   Jimenez Brito, G ^c   Sanchez Sosa S ^d   Perez Romano B ^a   Garces Eisele J ^a,d   Camacho Alarcon C ^a,d   Reyes Nunez V ^a   Sandoval Cruz, M ^b   Mendoza Pinto, C ^b   Lopez Colombo A ^b  

^a Laboratorios Clinicos de Puebla   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c El Colegio de Puebla   (Mexico)

^d UNIVERSIDAD POPULAR AUTÓNOMA DEL ESTADO DE PUEBLA   (Mexico)

Author keywords

Anti CD20; MabThera ; Rituxan ; Rituximab; Vitiligo

Indexed keywords

CD20 ANTIBODY; CHIMERIC ANTIBODY; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE; MELANOCYTE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; VITILIGO;

ANTI-CD20; MABTHERA®; RITUXAN®; RITUXIMAB; VITILIGO;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BIOMARKERS, PHARMACOLOGICAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; INFUSIONS, INTRAVENOUS; MICE; PILOT PROJECTS; RECOMBINANT FUSION PROTEINS; TH1-TH2 BALANCE; TREATMENT OUTCOME; VITILIGO;

EID: 84885114402     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12168     Document Type: Article

References (46)

1. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38:647-666.
2. Porter J, Beuf AH, Lerner AB, Nordlund JJ. Response to cosmetic disfigurement: patients with vitiligo. Cutis 1987; 39:493-494.
3. Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry 1979; 1:73-77.
4. Van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001; 81:1061-1067.
5. Kemp EH, Waterman EA, Weetman AP. Immunological pathomechanisms in vitiligo. Exp Rev Mol Med 2001; 3:1-22.
6. Uchi H, Stan R, Turk MJ etal. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 2006; 90:215-241.
7. Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA. Childhood vitiligo. J Am Acad Dermatol 1987; 16:948-954.
8. Park S, Albert DM, Bolognia JL. Ocular manifestations of pigmentary disorders. Dermatol Clin 1992; 10:609-622.
9. Ochi Y, DeGroot LJ. Vitiligo in Graves' disease. Ann Intern Med 1969; 71:935-940.
10. Gould IM, Gray RS, Urbaniak SJ, Elton RA, Duncan LJ. Vitiligo in diabetes mellitus. Br J Dermatol 1985; 113:153-155.
11. Cato AC, Wade E. Molecular mechanisms of anti-inflammatory action of glucocorticoids. Bioessays 1996; 18:371-378.
12. Hill LL, Shreedhar VK, Kripke ML, Owen Schaub LB. A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med 1999; 189:1285-1294.
13. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N. The role of tyrosine in autoinmune vitiligo. Lancet 1994; 344:1049-1052.
14. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg 2009; 28:86-89.
15. Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo. Autoimmun Rev 2010; 9:516-520.
16. Gulhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dermatol 1995; 105:683-686.
17. Ruiz-Argüelles A, Jimenez-Brito G, Reyes-Izquierdo P, Pérez-Romano B, Sánchez-Sosa S. Apoptosis of melanocytes in vitiligo results from antibody penetration. J Autoimmun 2007; 29:281-286.
18. Sandoval-Cruz M, Garcia-Carrasco M, Sanchez-Porras R etal. Immunopathogenesis of vitiligo. Autoimmun Rev 2011; 10:762-765.
19. Sánchez-Sosa S, Aguirre-Lombardo M, Jimenez-Brito G, Ruiz-Argüelles A. Immunophenotypic characterization of lymphoid cell infiltrates in vitiligo. Clin Exp Immunol 2013; 173:179-183.
20. Ioannou Y, Isenberg A. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002; 78:599-606.
21. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2006; 2:20-27.
22. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2:764-766.
23. Sabahi R, Anolik JH. B-cell-targeted therapy for systemic lupus erythematosus. Drugs 2006; 66:1933-1948.
24. Looney RJ, Anolik JH, Campbell D etal. B cell depletion as a novel treatment of systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580-2589.
25. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxf) 2005; 44:1542-1545.
26. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007; 66:1259-1262.
27. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis. Arthritis Rheum 2006; 54:2970-2982.
28. Gillis JZ, Dall'Era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a cases series. Arthritis Rheum 2007; 57:538-542.
29. Gunnarsson I, Sundeli B, Jonsdottir T, Johnston SH, Heriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56:1263-1272.
30. Sfikakis PP, Boletis JN, Lionaki S etal. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T-cell costimulatory molecule CD40 ligand: an open label trial. Arthritis Rheum 2005; 52:501-513.
31. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O etal. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to convencional therapy: a pilot study. Arthritis Res Ther 2006; 8:R83.
32. Tokunaga M, Saito K, Kawabata D etal. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving central nervous systemic. Ann Rheum Dis 2007; 66:470-475.
33. Kirschbaum SS, Schneerson DD, Pandolfi CA. Severe burns; therapy, homografts. Dia Med 1954; 26:465-472.
34. Joyner A, Wall N. Immunohistochemistry of whole-mount mouse embryos. CSH Protoc 2008; 2008:pdb.prot4820. doi:10.1101/pdb.prot4820.
35. Burnett R, Guichard Y, Barale E. Immunohistochemistry for light microscopy in safety evaluation of therapeutic agents: an overview. Toxicology 1997; 119:83-93.
36. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol 2005; 42:405-426.
37. Jiménez-Brito G, Garza-de-La-Peña E, Pérez-Romano B, Ruiz-Argüelles A. Serum antibodies to melanocytes in patients with vitiligo are predictors of disease progression. Skinmed 2013; in press.
38. Denham E, Mohn B, Tucker L, Lun A, Cleave P, Boswell DR. Evaluation of immunoturbidimetric specific protein methods using the Architect ci8200: comparison with immunonephelometry. Ann Clin Biochem 2007; 44:529-536.
39. Orfao A, Ruiz-Argüelles A. General concepts about cell sorting techniques. Clin Biochem 1996; 29:5-9.
40. Ruiz-Argüelles A. Flow cytometry in the clinical laboratory. Principles, applications and problems. Clin Chim Acta 1992; 211:S13-27.
41. *04 is associated with the genetic susceptibility to develop vitiligo in Mexican patients with autoimmune thyroid disease. J Am Acad Dermatol 2005; 52:182-183.
42. Inoko H, Ota M. PCR-RFLP. In: Hui KM, Bidwell JL, eds. Handbook of HLA typing techniques. Boca Raton: CRC Press, 1993:9-70.
43. Basra MKA, Shahrukh M. Burden of skin diseases. Exp Rev Pharmacoecon Outcomes Res 2009; 9:271-283.
44. Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 1995; 190:109-115.
45. Porter J, Beuf A, Lerner A, Nordlund J. Psychosocial effect of vitiligo: a comparison of vitiligo patients with 'normal' control subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol 1986; 15:220-224.
46. Ahmed I, Ahmed S, Nasreen S. Frequency and pattern of psychiatric disorders in patients with vitiligo. J Ayub Med Coll Abbottabad 2007; 19:19-21.